Literature DB >> 27492456

Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.

Yi Zhe1, Yan Li2, Dan Liu3, Dong-Ming Su4, Jin-Gang Liu3, Hang-Yu Li5.   

Abstract

Heat shock protein 70 (HSP70) and HSP70-peptide complexes (HSP70-PCs) have been implicated in the pathogenesis of multiple tumors in humans and have been experimentally shown to increase the proliferation of cell lines derived from hepatocellular carcinoma. The goal of this study was to elucidate the molecular mechanisms through which extracellular HSP70/HSP70-PCs stimulate the proliferation of hepatocellular carcinoma (HCC). The molecular mechanisms of HSP70/HSP70-PC action were studied in the human hepatocellular carcinoma cell lines HepG2 and Huh-7, as well as tumor tissue collected from patients with HCC (n = 95). We found that HSP70/HSP70-PCs can stimulate the proliferation of HepG2 cells and that this effect is blocked by knocking down TLR2 and TLR4 expression by RNA interference. A physical interaction between HSP70/HSP70-PCs and TLR2/4 was established using co-immunoprecipitation and pull-down assays. Pharmacological inhibition of different branches of the MAPK intracellular signaling pathway indicated that the extracellular HSP70/HSP70-PC effect was mediated by the JNK1/2 signaling pathway within the cell. We also studied TLR2 and TLR expression at the protein and messenger RNA (mRNA) level in tumor and non-tumor tissue in patients with HCC (n = 95), finding that TLR2 and 4 are increased in HCC tumor tissue and that the expression of TLR2 correlates with clinicopathologic features of HCC. Our data conclusively demonstrates that extracellular HSP70/HSP70-PCs can promote the proliferation of HCC cells through activation of TLR2 and TLR4 and subsequent activation of the intracellular JNK1/2/MAPK signaling pathway.

Entities:  

Keywords:  Extracellular HSP70-PCs; Hepatocellular carcinoma; JNK1/2MAPK; Proliferation; TLR2; TLR4

Mesh:

Substances:

Year:  2016        PMID: 27492456     DOI: 10.1007/s13277-016-5189-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  39 in total

1.  Heat shock protein 70 is secreted from tumor cells by a nonclassical pathway involving lysosomal endosomes.

Authors:  Salamatu S Mambula; Stuart K Calderwood
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

2.  MAPK/ERK2 phosphorylates ERG at serine 283 in leukemic cells and promotes stem cell signatures and cell proliferation.

Authors:  Y Huang; J A I Thoms; M L Tursky; K Knezevic; D Beck; V Chandrakanthan; S Suryani; J Olivier; A Boulton; E N Glaros; S R Thomas; R B Lock; K L MacKenzie; J H Bushweller; J W H Wong; J E Pimanda
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

Review 3.  Modulation of Toll-like receptor signaling in innate immunity by natural products.

Authors:  Luxi Chen; Jianhua Yu
Journal:  Int Immunopharmacol       Date:  2016-02-15       Impact factor: 4.932

4.  A systematic investigation based on microRNA-mediated gene regulatory network reveals that dysregulation of microRNA-19a/Cyclin D1 axis confers an oncogenic potential and a worse prognosis in human hepatocellular carcinoma.

Authors:  Yanqiong Zhang; Xiaodong Guo; Zhiwei Li; Boan Li; Zhiyan Li; Ruisheng Li; Qiuyan Guo; Lu Xiong; Lingxiang Yu; Jingmin Zhao; Na Lin
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

5.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

6.  Tonicity enhancer binding protein (TonEBP) and hypoxia-inducible factor (HIF) coordinate heat shock protein 70 (Hsp70) expression in hypoxic nucleus pulposus cells: role of Hsp70 in HIF-1α degradation.

Authors:  Shilpa S Gogate; Nobuyuki Fujita; Renata Skubutyte; Irving M Shapiro; Makarand V Risbud
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

7.  GM-CSF induces cyclin D1 expression and proliferation of endothelial progenitor cells via PI3K and MAPK signaling.

Authors:  Chaolin Qiu; Qiuhua Xie; Dongqing Zhang; Qing Chen; Jinhui Hu; Limin Xu
Journal:  Cell Physiol Biochem       Date:  2014-03-07

8.  A critical role for MAPK signalling pathways in the transcriptional regulation of toll like receptors.

Authors:  Marylene Y Peroval; Amy C Boyd; John R Young; Adrian L Smith
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

9.  HIV-1 Structural Proteins Serve as PAMPs for TLR2 Heterodimers Significantly Increasing Infection and Innate Immune Activation.

Authors:  Bethany M Henrick; Xiao-Dan Yao; Kenneth Lee Rosenthal
Journal:  Front Immunol       Date:  2015-08-19       Impact factor: 7.561

10.  GATA-2 transduces LPS-induced il-1β gene expression in macrophages via a toll-like receptor 4/MD88/MAPK-dependent mechanism.

Authors:  Tsu-Tuan Wu; Yu-Ting Tai; Yih-Giun Cherng; Tyng-Guey Chen; Chien-Ju Lin; Ta-Liang Chen; Huai-Chia Chang; Ruei-Ming Chen
Journal:  PLoS One       Date:  2013-08-06       Impact factor: 3.240

View more
  9 in total

1.  Prognostic impact of toll-like receptors 2 and 4 expression on monocytes in Egyptian patients with hepatocellular carcinoma.

Authors:  Asmaa M Zahran; Zeinab Albadry M Zahran; Omnia El-Badawy; Mona H Abdel-Rahim; Wageeh A M Ali; Amal Rayan; Muhammad Abbas El-Masry; Mohamed A A Abozaid; Helal F Hetta
Journal:  Immunol Res       Date:  2019-06       Impact factor: 2.829

2.  Are Pattern Recognition Receptors Associated with Hepatocellular Carcinoma?

Authors:  Ramazan Dertli; Mehmet Asil; Murat Bıyık; Ahmet Karakarcayıldız; Muharrem Keskin; Yusuf Kayar; Müşerref Başdemirci; Hüseyin Ataseven
Journal:  Turk J Gastroenterol       Date:  2021-07       Impact factor: 1.852

3.  Design and optimisation of a small-molecule TLR2/4 antagonist for anti-tumour therapy.

Authors:  Qun Xu; Tian Li; Hekai Chen; Jun Kong; Liwei Zhang; Hang Yin
Journal:  RSC Med Chem       Date:  2021-09-07

4.  Topical heat shock protein 70 prevents imiquimod-induced psoriasis-like inflammation in mice.

Authors:  Federico G Seifarth; Julia E-M Lax; Jennifer Harvey; Paul E DiCorleto; M Elaine Husni; Unnikrishnan M Chandrasekharan; Michael Tytell
Journal:  Cell Stress Chaperones       Date:  2018-04-03       Impact factor: 3.667

5.  HSP70-Homolog DnaK of Pseudomonas aeruginosa Increases the Production of IL-27 through Expression of EBI3 via TLR4-Dependent NF-κB and TLR4-Independent Akt Signaling.

Authors:  Jisu Jeon; Yeji Lee; Hyeonseung Yu; Un-Hwan Ha
Journal:  Int J Mol Sci       Date:  2020-12-02       Impact factor: 5.923

6.  Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma.

Authors:  Cheng Zhang; Ning Wang; Hor-Yue Tan; Wei Guo; Feiyu Chen; Zhangfeng Zhong; Kwan Man; Sai Wah Tsao; Lixing Lao; Yibin Feng
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

Review 7.  Role of MicroRNAs Induced by Chinese Herbal Medicines Against Hepatocellular Carcinoma: A Brief Review.

Authors:  Ge Guo; Juhua Zhou; Xiaogaung Yang; Jiang Feng; Yanxia Shao; Tingting Jia; Qingrong Huang; Yanmin Li; Yin Zhong; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  Integr Cancer Ther       Date:  2018-10-20       Impact factor: 3.279

8.  Prognostic role of Toll-like receptors in cancer: a meta-analysis.

Authors:  Qingwen Wang; Xiankai Zhang; Tingting Xiao; Chenhua Pan; Xing Liu; Yulan Zhao
Journal:  Ther Clin Risk Manag       Date:  2018-07-30       Impact factor: 2.423

9.  Long Noncoding RNA NONHSAT079852.2 Contributes to GBM Recurrence by Functioning as a ceRNA for has-mir-10401-3p to Facilitate HSPA1A Upregulation.

Authors:  Ningning Zhao; Jiajie Zhang; Lili Zhao; Xiaoni Fu; Qian Zhao; Min Chao; Haiyan Cao; Yang Jiao; Yaqin Hu; Chao Chen; Liang Wang; Huijuan Wang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.